<DOC>
	<DOCNO>NCT00493298</DOCNO>
	<brief_summary>The primary objective study ass long-term safety impact disease activity progression natalizumab participant relapse remit multiple sclerosis ( RRMS ) clinical practice setting .</brief_summary>
	<brief_title>Tysabri Observational Program</brief_title>
	<detailed_description>TOP epidemiological observational study participant receive natalizumab , participant follow 10 year . This study design address long-term safety profile long-term impact disease activity progression natalizumab market use , impact treatment disability particular comparing result prospectively determine control establish database .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Documented diagnosis Relapsing Remitting Multiple Sclerosis The decision treat Tysabri must precede enrollment Patient must new Tysabri user , must 3 Tysabri infusion prior enrollment Must least one relapse previous year , must satisfy locally approve therapeutic indication Tysabri Key History Progressive Multifocal Leukoencephalopathy opportunistic infection , increase risk opportunistic infection History positive antinatalizumab antibody Concomitant Immunomodulatory immunosuppressive therapy therapy Tysabri Patient immunocompromised time enrollment Known active malignancy Women must breast feeding pregnant , plan become pregnant ( must use birth control unless surgically sterile ) NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>disease progression</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>disease activity</keyword>
	<keyword>Tysabri</keyword>
	<keyword>natalizumab</keyword>
	<keyword>long-term safety</keyword>
</DOC>